首页> 外文期刊>Clinical chemistry and laboratory medicine: CCLM >B-type natriuretic peptide measurement in primary care; magnitude of associations with cardiovascular risk factors and their therapies. Observations from the STOP-HF (St. Vincent's Screening TO Prevent Heart Failure) study.
【24h】

B-type natriuretic peptide measurement in primary care; magnitude of associations with cardiovascular risk factors and their therapies. Observations from the STOP-HF (St. Vincent's Screening TO Prevent Heart Failure) study.

机译:初级保健中的B型利钠肽测量;与心血管危险因素及其治疗的关联程度。 STOP-HF(预防心力衰竭的圣文森特筛查)研究的观察结果。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: An effective prevention strategy for heart failure in primary care requires a reliable screening tool for asymptomatic ventricular dysfunction. Preliminary data indicate that B-type natriuretic peptide (BNP) may be suitable for this task. However, for the most effective use of this peptide, the interrelationships between associated risk factors and their therapies on BNP, and in particular their magnitude of effect, needs to be established in a large primary care population. Therefore, the objective of the study was to establish the extent of the association between BNP, cardiovascular risk factors and their therapies. METHODS: BNP measurement and clinical review was preformed on 1122 primary care patients with cardiovascular risk factors. Multivariate analyses identified significant associates of BNP concentrations which were further explored to establish the magnitude of their association. RESULTS: Associates of BNP were age (1.36-fold increase in BNP/decade), female (1.28), beta-blockers (1.90), myocardial infarction (1.36), arrhythmia (1.98), diastolic blood pressure; all p<0.01. A novel method was devised that plotted median BNP per sliding decade of age for the various combinations of these principal associates. CONCLUSIONS: The data presented underline the importance of considering several clinical and therapeutic factors when interpreting BNP concentrations. Most of these variables were associated with increased concentrations, which may in part explain the observed false-positive rates for detecting ventricular dysfunction using this peptide. Furthermore, the design of studies or protocols using BNP as an endpoint or a clinical tool should take particular account of these associations. This analysis provides the foundation for age, risk factor and therapy adjusted reference ranges for BNP in this setting.
机译:背景:在初级保健中有效的预防心力衰竭的策略需要可靠的无症状心室功能障碍筛查工具。初步数据表明B型利钠肽(BNP)可能适合此任务。然而,为了最有效地使用该肽,需要在大量的初级保健人群中建立相关风险因素与其对BNP的治疗之间的相互关系,尤其是其作用程度。因此,本研究的目的是确定BNP,心血管危险因素及其治疗之间的关联程度。方法:对1122名有心血管危险因素的初级保健患者进行了BNP测量和临床回顾。多变量分析确定了BNP浓度的显着相关因素,并对其进行了进一步探讨以建立其相关程度。结果:BNP的相关者是年龄(BNP /十年增加1.36倍),女性(1.28),β受体阻滞剂(1.90),心肌梗塞(1.36),心律不齐(1.98),舒张压;全部p <0.01。设计了一种新颖的方法,绘制了这些主要同伴的各种组合的每滑动十年的中值BNP。结论:所提供的数据强调了在解释BNP浓度时考虑多种临床和治疗因素的重要性。这些变量大多数与浓度增加有关,这可能部分解释了使用该肽检测到的心室功能障碍的假阳性率。此外,使用BNP作为终点或临床工具的研究或方案的设计应特别考虑这些关联。该分析为这种情况下BNP的年龄,危险因素和治疗调整后的参考范围提供了基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号